Abstract
The QRS interval of 56 out of 75 (74.7%) HIV-infected, drug-experienced patients (66.7% men) increased during treatment with boosted or unboosted atazanavir by a median 5 ms (interquartile range 0-9; P < 0.0001); the PR and the QTc intervals did not change significantly. New asymptomatic bundle branch blocks were observed in four patients; one subject with a baseline first-degree atrioventricular block developed symptomatic bradyarrhythmia while receiving atenolol. The electrocardiographic monitoring of patients treated with atazanavir seems advisable.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Atazanavir Sulfate
-
Bundle-Branch Block / chemically induced*
-
Drug Monitoring / methods
-
Electrocardiography / drug effects
-
Female
-
Follow-Up Studies
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / adverse effects*
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Oligopeptides / adverse effects*
-
Oligopeptides / therapeutic use
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
Substances
-
HIV Protease Inhibitors
-
Oligopeptides
-
Pyridines
-
Atazanavir Sulfate